BIO-TECHNE (TECH) Company Report

Bio-Techne reported $1.2 billion in revenue for 2025, with 81% consumables, 9% instruments, 7% services, and 2% royalties, operating in two segments: protein sciences and diagnostics & spatial biology.
The company targets three high-growth verticals: cell therapies in a $2 billion TAM growing ~20% annually, proteomic applications in a $4 billion addressable market, and spatial biology in a $5 billion market, contributing to a $27 billion total addressable market.
Innovation priorities include AI-designed proteins and the ProPak cytokine delivery system for cell therapy, the Simple Western Leo and ultra-sensitive Ella cartridges for proteomics, and expanded multi-omic capabilities via RNAscope and COMET.
Financially, Bio-Techne has achieved a 10% revenue CAGR over five years, delivered 5% organic growth in fiscal 2025 with 9% operating margin, and targets 35–40% operating margins going forward.
M&A remains strategic: the company holds 20% of Wilson Wolf with plans to acquire the remainder by end of 2027, reinforcing its position in cell therapy bioreactors.

1 day ago

Transcript

Bio-Techne provides strategic overview at 44th J.P. Morgan Healthcare Conference

TECH

Guidance Update

Product Launch

M&A

Bio-Techne reported $1.2 billion in 2025 revenue, driven by 81% consumables with a segment mix of 73% protein sciences and 27% diagnostics & spatial biology. The company delivered a 10% five-year CAGR, 5% organic growth in fiscal 2025, and targets 35–40% operating margins.
The firm addresses a combined $27 billion total addressable market across three growth verticals—discovery, advanced therapeutics manufacturing, and precision diagnostics—and leverages a differentiated portfolio in cell therapies, proteomic analytics, and spatial biology.
Bio-Techne reaffirmed low single-digit revenue growth guidance for fiscal 2026, assuming an “air pocket” due to delayed orders from fast-track cell therapy customers and gradual market recovery.
Upcoming and recent product innovations include AI-designed proteins and ProPak cytokine delivery for cell therapies; the Simple Western Leo and ultra-sensitive Ella immunoassays for proteomic analysis; and enhanced RNAscope proximity assays alongside the COMET multi-omic spatial platform.
The company holds a 20% stake in Wilson Wolf and plans to acquire the remaining interest by end of calendar 2027, integrating the G-Rex disposable bioreactor into its cell therapy solutions.

1 day ago

Transcript

Bio-Techne outlines 2026 strategy at J.P. Morgan Healthcare Conference

TECH

Bio-Techne reported $1.2 billion in 2025 revenue, comprised of 81% consumables, 9% instruments, 7% services and 2% royalties, with 12% of consumables tied to installed instruments.
Revenues split 73% to Protein Sciences and 27% to Diagnostics & Spatial Biology, the latter down slightly after the Exosome Diagnostics divestiture.
The company is targeting three high-growth applications: cell therapies (addressable market of $2 billion, ~20% CAGR) , proteomic analytical instruments ($4 billion TAM) , and spatial biology ($5 billion market).
Over the past five years, Bio-Techne delivered a 10% revenue CAGR and in FY 2025 achieved 5% organic growth with a 9% operating margin, underpinned by productivity and strategic investment.

1 day ago

Transcript

Bio-Techne presents January 2026 corporate strategy and growth

TECH

FY2025 revenue exceeded $1.2 billion, driven by Protein Sciences (73 %) and Diagnostics & Spatial Biology (27 %).
Adjusted operating income reached $384 million in 2025, up from $246 million in 2020.
Company addresses a $27 billion total addressable market, including $14 billion in discovery, $5 billion in advanced therapeutics, and $8 billion in precision diagnostics.
Focused on three strategic growth vectors: cell-based systems & therapies, high-value proteomic applications, and spatial multiomic interrogation.

2 days ago

Presentation

Bio-Techne outlines growth drivers and Fiscal 2026 outlook at Nasdaq Investor Conference

TECH

Guidance Update

Bio-Techne leverages a 50-year core reagents business with four high-growth verticals: cell therapy, proteomics, spatial biology, and molecular diagnostics.
Q1 FY2026 highlights include double-digit growth in large pharma, China back to growth, spatial biology bookings up double digits, and margins of 29.9% versus a 20% forecast, offset by a near-term “air pocket” in cell therapy after two customers received FDA Fast Track approvals.
Biopharma represents 50% of revenue with large pharma (30% of revenue) growing double digits and biotech pressured by mid-teens funding declines but showing improvement; academic research (20% of revenue) faces US budget uncertainty with funding shifting toward neurology, oncology, and weight management.
Full-year FY2026 guidance expects single-digit growth as headwinds in biotech and academic markets persist, with management targeting a return to double-digit growth in a normalized environment and anticipating easier comps in the back half of the year.

Dec 9, 2025, 9:30 AM

Transcript

Bio-Techne outlines growth strategy and Q1 2026 performance

TECH

Guidance Update

Product Launch

M&A

Bio-Techne detailed its core reagents applied across four high-growth verticals—cell therapy, proteomics, spatial biology, and molecular diagnostics—leveraging 7,000 proteins and 400,000 antibodies built over 50 years.
In Q1 FY2026, revenues benefited from Fast Track designations in cell therapy customers and growth in large pharma (double-digit for three consecutive quarters), China returned to positive growth, spatial biology bookings accelerated, and operating margin expanded to 29.9%.
The company launched several innovations, including ProPak form factors for cell therapy, the Leo high-throughput protein analysis instrument, multi-omics spatial assays, protein–protein interaction mapping, and an ESR1 breast cancer resistance diagnostic.
Bio-Techne expects single-digit growth in FY2026 due to academic funding and biotech headwinds, with markets stabilizing, easier comparables in H2, and a return to double-digit growth in normalized conditions.

Dec 9, 2025, 9:30 AM

Transcript

Bio-Techne outlines FY2025 outlook at Citi Healthcare Conference

TECH

Guidance Update

Demand Weakening

Q1 FY25 revenue declined –1% YoY; excluding headwinds from two large iPSC cell therapy customers (≈200 bps), underlying growth was +1%.
Q2 FY25 overall growth is guided at –1% YoY; adjusting for a 400 bps customer headwind, ex-customers growth is expected at +3%, driven by ProteinSimple and Spatial Biology in a stabilizing market.
Pharma end-market (30% of revenue) returned to double-digit growth in Q1 FY25, while U.S. academic sales improved to low single-digit declines as NIH funding stabilized around flat budgets.
Two fast-tracked iPSC customers paused purchases through FY25; commercialization is projected ~18 months post–Phase III, with each customer potentially generating $40 – 50 million annually at mid-maturity.
Diagnostics segment grew mid-single digits in Q1 FY25 on top of a mid-teen comp last year, with customers indicating a more even pull-through cadence across FY25.

Dec 3, 2025, 8:15 PM

Transcript

Bio-Techne outlines FY2025 growth drivers and headwinds

TECH

Guidance Update

Q1 FY25 revenue was -1%, with two large cell therapy customers contributing a 200 bps headwind; excluding them, growth was +1% and is forecasted at +3% ex-customers in Q2 (headwind of 400 bps).
Biotech funding improved from –30% to –13% YTD by November 2025, with a typical 2–3 quarter lag expected before supporting a Biotech end-market recovery around FY27.
ProteinSimple and Spatial Biology are key growth drivers: Spatial bookings rose double-digits in Q1 and reagents turned positive, while ProteinSimple historically outperforms in stabilized markets.
Diagnostics (controls, calibrators and exosome-based kits) grew mid-single digits in Q1 on top of mid-teen comps last year and is anticipated to be more evenly lumpy throughout FY25.
Company expects ~100 bps operating margin expansion for FY25, driven by higher consumables pull-through and improving organic growth; COMET platform break-even anticipated in ~1 year.

Dec 3, 2025, 8:15 PM

Transcript

TECH reports Q1 performance and end-market trends at HealthCONx Conference

TECH

Q1 organic revenue declined 1%, with 90 bps of margin expansion; results would have been a 1% increase excluding deferrals from two cell therapy customers after FDA Fast Track designations.
Large pharma (30% of revenues) achieved its third consecutive quarter of double-digit growth; China posted its second straight quarter of organic revenue growth.
The Spatial platform stabilized at flat growth, reagents turned positive, and instrument bookings rose double digits, indicating a recovery in the academic/biotech segment.
Small biotech (~20% of revenue) fell high single digits in Q1 amid a 30% YTD drop in funding, but funding has improved monthly, suggesting market stabilization ahead.
Academic & government (~20% of revenue) saw mid-single-digit growth in Europe and U.S. declines narrowed to low single digits as flat NIH budgets became more likely.

Dec 2, 2025, 1:20 PM

Transcript

Bio-Techne reports Q1 fiscal 2026 results and outlook at Evercore HealthCONx

TECH

Guidance Update

Demand Weakening

Q1 organic revenue declined by 1%, driven by double-digit growth in large pharma (30% of revenue), second quarter of organic growth in China, robust ProteinSimple consumables, spatial stabilization, and 90 bps margin expansion despite cell therapy headwinds.
Biotech exposure (~20% of revenue) fell high single digits in Q1 amid a 30% YTD funding decline, but four consecutive months of year-over-year funding increases point to market stabilization.
Academic & government segment (~20% of revenue) saw mid-single-digit growth in Europe and US declines narrow from high to low single digits as NIH budget is expected to be flat, reducing customer uncertainty.
The company expects Q2 results similar to Q1, with underlying markets to strengthen to low single-digit growth, and the back half of fiscal 2026 poised to benefit from easier year-over-year comps and share gains.
FDA Fast Track consolidation of Phase II/III for two cell therapy customers caused a ~$26 M headwind (~200 bps) in fiscal 2026; the cell & gene portfolio includes ~700 customers with ~85 in clinical trials, and the Wilson Wolf acquisition is planned for fiscal 2028 to fuel future growth.

Dec 2, 2025, 1:20 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for BIO-TECHNE.

Q1 2026

Nov 5, 2025

→

Q4 2025

Aug 6, 2025

→

Q3 2025

May 7, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Kim Kelderman say about margins?What are BIO-TECHNE's strategic priorities?How is BIO-TECHNE positioned vs competitors?How did BIO-TECHNE do last quarter?

BIO-TECHNE (TECH)

Analyst Earnings Quarterly Reports

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Executives

Kim Kelderman

James Hippel

Matthew McManus

Shane Bohnen

William Geist

Board Members

Alpna Seth

Amy Herr

John Higgins

Joseph Keegan

Judith Klimovsky

Julie Bushman

Robert Baumgartner

Rupert Vessey

Analyst Coverage

Puneet Souda

Daniel Leonard

Matthew Larew

Patrick Donnelly

Sung Ji Nam

Daniel Arias

Daniel Markowitz

Brandon Couillard

Catherine Schulte

Conor Noel McNamara

Dan Arias

Dan Leonard

Hannah Hefley

Jacob Johnson

Justin Bowers

Kyle Boucher

Mac Etoch

Matt Larew

Paul Knight

Thomas Peterson

Tom DeBourcy

Latest news

Earnings Transcripts

Q1 2026

Q4 2025

Q3 2025

Ask Fintool AI Agent